Knowing Is Not Enough, We Must Apply: SGLT2 I...

Discover how emerging targeted therapies address systemic drivers in MASLD and MASH. Credit available for this activity expires: 9/8/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/targeting-metabolic-driver-forward-looking-approach-obesit ...  Show more

Fatigue, unpredictability, and life goals; integrate what patients say they need into how you treat myasthenia gravis (MG). Credit available for this activity expires: 9/4/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/whole-patient-integ ...  Show more

Drs Sparks and Neuen discuss the proper use of SGLT2 inhibitors to prevent chronic kidney disease, including how to start them and monitor them and their possible side effects. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/vie ...  Show more

CardioNerds Drs. Jason Feinman, Gurleen Kaur, and Rick Ferraro discuss the implementation of SGLT inhibitors in clinical practice with Dr. Alison Bailey. Notes were drafted by Dr. Jason Feinman. In this episode, we discuss the implementation of SGLTi in clinical practice scenario ...  Show more

SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare profe ...

Dr. Centor discusses the indications for prescribing sodium-glucose cotransporter-2 inhibitors for patients with heart failure with observed ejection fraction with Dr. Sarah Adie.